ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2586

Comparison of Intra-Articular Methylprednisolone Acetate with Triamcinolone Acetonide in Acutely Swollen Knee Joint of Patients with Chronic Inflammatory Arthritis – a Randomized Controlled Trial  

Ashwani Kumar1, Varun Dhir2, Aman Sharma3, Shefali Sharma4 and Surjit Singh5, 1Postgraduate Institute of Medical Education and Research, Chandigarh, India, Chandigarh, India, 2Internal Medicine (Rheumatology Unit), Postgraduate Institute of Medical Education and Research, Chandigarh, India, 3Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India, 4Postgraduate Institute of Medical Education and Research, Chandigarh, India, 5Department of Internal Medicine,, Postgraduate Institute of Medical Education and Research, Chandigarh, India

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: corticosteroids, joint procedures and rheumatoid arthritis (RA), Knee

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 15, 2016

Title: Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Intra-articular steroids are in use since half-a-century, but choice of individual agents remains empirical in the absence of comparative trials. This study compared the efficacy of intra-articular injection of methylpredisolone acetate (MPA) with triamcinolone acetonide (TA) in treatment of acutely swollen knee joint in patients with chronic inflammatory arthritis.

Methods: This was a double-blind randomized controlled trial that included patients with rheumatoid arthritis (RA) or spondyloarthritis (SpA) having an acutely swollen knee (>1 week and <24 weeks). Patients were randomized (1:1) to receive intra-articular injection of either methylpredisolone acetate (MPA) or triamcinolone acetonide (TA) (80 mg, 2ml) and followed over 24 weeks. The primary outcome measure was time-to-relapse and secondary outcome measures were numerical rating scale (NRS) (0-10) of pain and swelling at 4, 12 and 24 weeks, range of motion and adverse effects. In addition assessed change in DAS28-3, Indian health assessment questionnaire and proportion with good improvement (>50% improvement). Primary analysis was intention-to-treat; in addition per-protocol (only completers) analysis also done. Trial # Clinical trials registry of India CTRI/2015/09/006187

Results: This study included 100 patients (RA:SpA=89:11, M:F=24:76). They were randomized (50 each) to MPA and TA, with no significant differences in baseline characteristics. At 24 weeks, 3 patients were lost and 9 relapsed in each group, with no significant difference in mean (+/-SEM) time-to-relapse (20.8±1.0, 20.9±1.0 weeks, p=0.96) (Figure 1). There was also no significant difference in change in NRS pain (-4.4±3.1, -3.9±2.8, p=0.46) and NRS swelling (-4.5±2.9, -3.9±2.8, p=0.36) in MPA and TA groups at 24 weeks from baseline. (Figure 2) At baseline, normal flexion of knee joint was present in 28 and 25 patients (p=0.17), and at 24 weeks, in 38 and 37 patients (p=0.7) respectively. There were no adverse effects in any patient. There was no significant difference in the change in DAS28-3 at 24 weeks from baseline (-1.4±1.1, -1.3±1.3) or in HAQ at 24 weeks from baseline (-0.7±0.5, -0.7±0.5, p=0.80).

Conclusion: There was no significant difference efficacy of intra-articular injection of MPA vs TA in knee arthritis over a period of 24 weeks. Figure 1:Kapan-Meier curve comparing time-to-relapse in MPA and TA groups

Figure 2: Composite outcomes over 24 weeks in the MPA and TA groups


Disclosure: A. Kumar, None; V. Dhir, None; A. Sharma, None; S. Sharma, None; S. Singh, None.

To cite this abstract in AMA style:

Kumar A, Dhir V, Sharma A, Sharma S, Singh S. Comparison of Intra-Articular Methylprednisolone Acetate with Triamcinolone Acetonide in Acutely Swollen Knee Joint of Patients with Chronic Inflammatory Arthritis – a Randomized Controlled Trial   [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/comparison-of-intra-articular-methylprednisolone-acetate-with-triamcinolone-acetonide-in-acutely-swollen-knee-joint-of-patients-with-chronic-inflammatory-arthritis-a-randomized-controlled-tr/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparison-of-intra-articular-methylprednisolone-acetate-with-triamcinolone-acetonide-in-acutely-swollen-knee-joint-of-patients-with-chronic-inflammatory-arthritis-a-randomized-controlled-tr/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology